Alaproclate

Alaproclate

Systematic (IUPAC) name
1-(4-Chlorophenyl)-2-methylpropan-2-yl 2-aminopropanoate
Clinical data
Legal status	Uncontrolled
Routes of administration	Oral
Identifiers
CAS Number	60719-82-6 N Template:CAS (hydrochloride)
ATC code	N06AB07 (WHO)
PubChem	CID: 2081
ChemSpider	1997 Y
UNII	C4R42570ZO Y
KEGG	D02787 Y
ChEMBL	CHEMBL36591 Y
Chemical data
Formula	C13H18ClNO2
Molecular mass	255.740 g/mol
SMILES Clc1ccc(cc1)CC(OC(=O)C(N)C)(C)C
InChI InChI=1S/C13H18ClNO2/c1-9(15)12(16)17-13(2,3)8-10-4-6-11(14)7-5-10/h4-7,9H,8,15H2,1-3H3 Y Key:FZSPJBYOKQPKCD-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Alaproclate (INN, USAN) (developmental code name GEA-654) is a drug that was being developed as an antidepressant by the Swedish pharmaceutical company Astra AB (now AstraZeneca) in the 1970s. It acts as a selective serotonin reuptake inhibitor (SSRI), and along with zimelidine and indalpine, was one of the first of its kind. Development was discontinued due to the observation of liver complications in rodent studies. In addition to its SSRI properties, alaproclate has been found to act as a non-competitive NMDA receptor antagonist, but does not have discriminative stimulus properties similar to phencyclidine.

See also

• Femoxetine
• Indalpine
• Zimelidine